María del Canto De Hoyos-Alonso

María del Canto De Hoyos-Alonso

Auto-generated profile, based on publicly available information

María del Canto De Hoyos-Alonso

Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Instituto de Salud Carlos III (ISCIII), Madrid, España

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2023 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
VGVictoria García-Martín
Victoria García-Martín
MHM Canto de Hoyos-Alonso
M Canto de Hoyos-Alonso
RDRosalía Delgado-Puebla
Rosalía Delgado-Puebla
GAGloria Ariza-Cardiel
Gloria Ariza-Cardiel
IGIsabel Del-Cura González
Isabel Del-Cura González
Background: Caregiver burden is related to personal factors and patient characteristics and is greater when neuropsychiatric symptoms (NPSs) are present. Objective: Estimate the prevalence of burden among caregivers of dementia patients and its association with NPSs and identify NPSs causing greater caregiver distress according to dementia stage. Methods: A cross-sectional observational study in caregivers of noninstitutionalized dementia patients was conducted. Caregiver variables were sociodemographic, time of care, NPS-associated distress based on the Neuropsychiatric Inventory Caregiver Distress Scale (NPI-D) and burden based on the Zarit Burden Interview (ZBI). Patient variables were time since disease onset, Global Deterioration Scale (GDS) disease stage, functional assessment and NPS presence and intensity according to the Neuropsychiatric Inventory (NPI). The mean ZBI score, prevalence of burden and NPI-D score with 95% CIs at each dementia stage were estimated. Factors associated with burden were identified by multivariate analysis. Results: Of the 125 caregivers included, 77.6% were women, with a mean age of 60.7 (± 14.3) years; 78.4% (95%CI: 71.0; 86.0) experienced burden. The mean ZBI score was 12.3 (95%CI: 11.6; 12.9) and increased according to NPS number (p = 0.042). The NPSs causing the most burden were disinhibition (93.5%), irritability (87.3%) and agitation (86.1%). Agitation, apathy, and sleep disorders were the NPSs generating the greatest overall caregiver distress; depression (max NPI-D 1.9), hyperactivity (max NPI-D 2.1), and psychosis symptoms (max NPI-D 1.6) generated the greatest distress at stage GDS 3, stages GDS 4–5, and stages GDS 6–7, respectively. The NPI score (OR = 1.0, 95%CI 1.0; 1.1), intensity of irritability (OR = 1.2, 95%CI 1.0; 1.6), disinhibition (OR = 2.6, 95%CI 1.1; 5.8) and hyperactivity subsyndrome (OR = 1.1, 95%CI 1.0; 1.2) were associated with caregiver burden. Other associated factors were female gender (OR = 6.0, 95%CI 1.6; 22.8), ≥ 8 h daily care (OR = 5.6, 95%CI 1.4; 22.8), working outside the home (OR = 7.6, 95%CI 1.8; 31.8), living with the patient (OR = 4.5, 95%CI 1.1; 19.6), kinship (OR = 5.4, 95%CI 1.0; 28.2) and lower patient education (OR = 8.3, 95%CI 2.3; 30.3). Conclusions: The burden on caregivers of dementia patients is high and associated with NPS presence and intensity. Disinhibition and irritability caused the highest burden. Depression, hyperactivity and psychosis produce more distress in mild, mild-moderate and severe dementia, respectively.

22 January 2022 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
VGVictoria García-Martín
Victoria García-Martín
MHM. Canto de Hoyos-Alonso
M. Canto de Hoyos-Alonso
GAGloria Ariza-Cardiel
Gloria Ariza-Cardiel
RDRosalía Delgado-Puebla
Rosalía Delgado-Puebla
PGPaula García-Domingo
Paula García-Domingo
ICIsabel del Cura-González
Isabel del Cura-González
Background: The objective was to describe the prevalence and intensity of neuropsychiatric symptoms (NPSs) isolated and grouped into subsyndromes in patients with dementia in primary care (PC) to analyse their distribution based on stages of dementia and the relationship between them and the intensity of symptoms.Methods: Design: Cross-sectional study. Setting and population: Patients with dementia, not institutionalized, in a PC follow-up. Variables: Sociodemographic and clinical variables. Assessment instruments: The frequency and intensity of NPSs were measured with the Neuropsychiatric Inventory (NPI), and the stages of dementia with the Global Deterioration Scale (GDS). Statistical analysis: The number of NPSs per patient, the mean NPI value, and the prevalence and intensity of NPSs isolated and grouped into subsyndromes were calculated, as were their 95% confidence intervals (CIs). The analyses were performed on an overall basis and by GDS scores. To analyse the association between the NPI and GDS scores, multivariate analysis was performed with a generalized linear model.Results: Overall, 98.4% (95% CI 94.5;99.8) of the patients presented some type of NPS, with an average of five symptoms per patient. The most frequent symptoms were apathy [69.8% (95% CI 61.1;77.5)], agitation [55.8% (95% CI 46.8;64.5)] and irritability [48.8% (95% CI 39.9;57.8)]. The more intense NPSs were apathy [NPI 3.2 (95% CI 2.5;3.8)] and agitation [NPI 3.2 (95% CI 2.5;4.0)]. For subsyndromes, hyperactivity predominated [86.0% (95% CI 78.8;91.5)], followed by apathy [77.5% (95% CI 69.3;84.4]). By phase of dementia, the most common isolated symptom was apathy (60.7–75.0%). Affective symptoms and irritability predominated in the initial stages, and psychotic symptoms predominated in advanced stages. The mean NPI score was 24.9 (95% CI 21.5;28.4) and increased from 15.6 (95% CI 8.2;23.1) for GDS 3 to 28.9 (95% CI 12.6;45.1) for GDS 7. Patients with in the most advanced stages of dementia presented an NPI score 7.6 (95% CI 6.8;8.3) points higher than the score for mild dementia with adjustment for the other variables.Conclusions: A high prevalence of NPSs was found among patients with dementia treated in PC. Symptoms change and increase in intensity as the disease progresses. Scales such as the NPI allow these symptoms to be identified, which may facilitate more stage-appropriate management.

16 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JRJesús Redondo-Sánchez
Jesús Redondo-Sánchez
RRRicardo Rodríguez-Barrientos
Ricardo Rodríguez-Barrientos
MDMª del Canto De-Hoyos-Alonso
Mª del Canto De-Hoyos-Alonso
CMCristina Muntañola-Valero
Cristina Muntañola-Valero
IMIsabel Almendro Martínez
Isabel Almendro Martínez
ICIsabel del Cura-González
Isabel del Cura-González
To analyse trends in urinary tract infection (UTIs) hospitalisation among patients adults 18–65 aged in Spain from 2000–2015. Retrospective observational study using the Spanish Hospitalisation Minimum Data Set (CMBD), with codifications by the International Classification of Diseases (ICD-9). Variables: Type of UTIs (pyelonephritis, prostatitis, cystitis and non-specific-UTIs), sex, age (in 5 categories: 18–49 and 50–64 years in men, and 18–44, 45–55 and 56–64 years in women), comorbidity, length of stay, costs and mortality associated with admission. The incidence of hospitalisation was studied according to sex, age group and type of UTIs per 100,000. Trends were identified using Joinpoint regression. From 2000–2015, we found 259,804 hospitalisations for UTIs (51.6% pyelonephritis, 7.5% prostatitis, 0.6% cystitis and 40.3% non-specific UTIs). Pyelonephritis predominated in women and non-specific UTIs in men. The hospital stay and the average cost (2,160 EUR (IQR 1,7872,540 were greater in men. Overall mortality (0.4%) was greater in non-specific UTIs. More women were admitted (rates of 79.4 to 81.7) than in men (30.2 to 41). The greatest increase was found in men aged 50–64 years (from 59.3 to 87). In the Joinpoint analysis, the incidence of pyelonephritis increased in women [AAPC 2.5(CI 95% 1.6;3.4)], and non-specific UTIs decreased [AAPC −2.2(CI 95% −3.3;-1.2)]. Pyelonephritis decreased in men [AAPC −0.5 (CI 95% −1.5;0.5)] and non-specific UTIs increased [AAPC 2.3 (CI 95% 1.9;2.6)] and prostatitis increased [AAPC 2.6 (CI 95% 1.4;3.7)]. The urinary infection-related hospitalisation rate in adults in Spain increased during the period 2000–2015. Pyelonephritis predominated in women and non-specific UTIs in men. The highest hospitalisation rates occurred in the women but the greatest increase was found in men aged 65–74. The lenght of stay and cost were higher in men.

3 July 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
CHCristina María Lozano Hernández
Cristina María Lozano Hernández
RMRodrigo Medina-García
Rodrigo Medina-García
MHMª Canto de Hoyos-Alonso
Mª Canto de Hoyos-Alonso
AGAraceli Garrido-Barral
Araceli Garrido-Barral
CMCésar Minué-Lorenzo
César Minué-Lorenzo
TCTeNDER Group Primary Care
TeNDER Group Primary Care
Background: Among chronic diseases, cognitive, neurological, and cardiovascular impairments are becoming increasingly prevalent, generating a shift in health and social needs. Technology can create an ecosystem of care integrated with microtools based on biosensors for motion, location, voice, and expression detection that can help people with chronic diseases. A technological system capable of identifying symptoms, signs, or behavioral patterns could provide notification of the development of complications of disease. This would help the self-care of patients with chronic disease and save health care costs, promoting the autonomy and empowerment of patients and their caregivers, improving their quality of life (QoL), and providing health professionals with monitoring tools. Objective: The main objective of this study is to evaluate the effectiveness of a technological system (the TeNDER system) to improve quality of life in patients with chronic diseases: Alzheimer disease, Parkinson disease, and cardiovascular disease. Methods: A multicenter, randomized, parallel-group clinical trial will be conducted with a follow-up of 2 months. The scope of the study will be the primary care health centers of the Community of Madrid belonging to the Spanish public health system. The study population will be patients diagnosed with Parkinson disease, Alzheimer disease, and cardiovascular disease; their caregivers; and health professionals. The sample size will be 534 patients (380 in the intervention group). The intervention will consist of the use of the TeNDER system. The system will monitor the patients by means of biosensors, and their data will be integrated into the TeNDER app. With the information provided, the TeNDER system will generate health reports that can be consulted by patients, caregivers, and health professionals. Sociodemographic variables and technological affinity will be measured, as will views on the usability of and satisfaction with the TeNDER system. The dependent variable will be the mean difference in QoL score between the intervention and control groups at 2 months. To study the effectiveness of the TeNDER system in improving QoL in patients, an explanatory linear regression model will be constructed. All analyses will be performed with the 95% CI and robust estimators. Results: Ethics approval for this project was received on September 11, 2019. The trial was registered on August 14, 2020. Recruitment commenced in April 2021, and the expected results will be available during 2023 or 2024. Conclusions: This clinical trial among patients with highly prevalent chronic illnesses and the people most involved in their care will provide a more realistic view of the situation experienced by people with long-term illness and their support networks. The TeNDER system is in continuous development based on a study of the needs of the target population and on feedback during its use from the users: patients, caregivers, and primary care health professionals. Trial Registration: ClinicalTrials.gov NCT05681065; https://clinicaltrials.gov/ct2/show/NCT05681065 International Registered Report Identifier (IRRID): DERR1-10.2196/47331

16 March 2023 in JMIR Preprints
Verified
Preprint
Open access
CHCristina María Lozano Hernández
Cristina María Lozano Hernández
RMRodrigo Medina-García
Rodrigo Medina-García
MHMª Canto de Hoyos-Alonso
Mª Canto de Hoyos-Alonso
AGAraceli Garrido-Barral
Araceli Garrido-Barral
CMCésar Minué-Lorenzo
César Minué-Lorenzo
IGIsabel Del-Cura González
Isabel Del-Cura González
BACKGROUND Among chronic diseases, cognitive, neurological, and cardiovascular impairments are becoming increasingly prevalent, generating a shift in health and social needs. Technology can create an ecosystem of care integrated with microtools based on biosensors for motion, location, voice, and expression detection that can help people with chronic diseases. A technological system capable of identifying symptoms, signs, or behavioral patterns could provide notification of the development of complications of disease. This would help the self-care of patients with chronic disease and save health care costs, promoting the autonomy and empowerment of patients and their caregivers, improving their quality of life (QoL), and providing health professionals with monitoring tools. OBJECTIVE The main objective of this study is to evaluate the effectiveness of a technological system (the TeNDER system) to improve quality of life in patients with chronic diseases: Alzheimer disease, Parkinson disease, and cardiovascular disease. METHODS A multicenter, randomized, parallel-group clinical trial will be conducted with a follow-up of 2 months. The scope of the study will be the primary care health centers of the Community of Madrid belonging to the Spanish public health system. The study population will be patients diagnosed with Parkinson disease, Alzheimer disease, and cardiovascular disease; their caregivers; and health professionals. The sample size will be 534 patients (380 in the intervention group). The intervention will consist of the use of the TeNDER system. The system will monitor the patients by means of biosensors, and their data will be integrated into the TeNDER app. With the information provided, the TeNDER system will generate health reports that can be consulted by patients, caregivers, and health professionals. Sociodemographic variables and technological affinity will be measured, as will views on the usability of and satisfaction with the TeNDER system. The dependent variable will be the mean difference in QoL score between the intervention and control groups at 2 months. To study the effectiveness of the TeNDER system in improving QoL in patients, an explanatory linear regression model will be constructed. All analyses will be performed with the 95% CI and robust estimators. RESULTS Ethics approval for this project was received on September 11, 2019. The trial was registered on August 14, 2020. Recruitment commenced in April 2021, and the expected results will be available during 2023 or 2024. CONCLUSIONS This clinical trial among patients with highly prevalent chronic illnesses and the people most involved in their care will provide a more realistic view of the situation experienced by people with long-term illness and their support networks. The TeNDER system is in continuous development based on a study of the needs of the target population and on feedback during its use from the users: patients, caregivers, and primary care health professionals. CLINICALTRIAL ClinicalTrials.gov NCT05681065; https://clinicaltrials.gov/ct2/show/NCT05681065 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/47331

25 March 2026 in PLOS ONE
Verified
Journal Article
Open access
ETEster Tapias-Merino
Ester Tapias-Merino
MHMaría del Canto De Hoyos-Alonso
María del Canto De Hoyos-Alonso
JRJavier Rubio-Serrano
Javier Rubio-Serrano
BABeatriz Arregui-Gallego
Beatriz Arregui-Gallego
ILIleana Gefaell Larrondo
Ileana Gefaell Larrondo
ICIsabel del Cura-González
Isabel del Cura-González
Background: Cardiovascular risk (CVR) factors increase the risk of cognitive impairment. Our objective was to assess the relationship between CVR and cognitive performance by sex in the Spanish population. Methods: Cross-sectional analysis nested within the population-based NEDICES-2 cohort. The included participants were 55–75 years old without previous cardiovascular events. CVR was estimated using the REGICOR and FRESCO risk equations. Outcome variable: performance on premorbid intelligence, global cognition, memory, verbal fluency, visuoconstruction, attention, and psychomotor speed. Generalized linear models were built. Results: 863 participants (56.0% women). Women with higher CVR estimated with FRESCO showed worse cognitive outcomes on Immediate memory test OR: 4.77 (CI95% 1.81–13.80), Delayed memory test OR: 2.86 (CI95% 1.09–7.91), Clock drawing test OR 3.23 (CI95% 1.07–10.10), TMTA-1 timing OR: 6.92 (CI95% 2.43–20.90) and TMTA-2 timing OR 3.89 (CI95% 1.34–11.50%). With moderate versus low CVR they scored worse on Clock drawing test OR 2.08 (CI95% 1.08–4.02), TMTA-1 timing OR: 2.99 (CI95% 1.62–5.58) and TMTA-2 timing OR 2.01 (CI95% 1.06–3.83%). Men with high versus low CVR with REGICOR had lower scores on MMSE-37 OR: 2.41 (CI95% 1.08–5.36), Word accentuation OR: 2.90 (CI95% 1.28–6.67), TMTA-1 OR: 3.68 (CI95% 1.57–8.71) and TMTA-2 OR: 2.82 (CI95% 1.24–6.41). With moderate versus low CVR, they scored worse on TMTA-1 OR: 2.21 (CI95% 1.15–4.41). With FRESCO, men with high versus low CVR were worse on Immediate memory OR: 2.23 (CI95% 1.07–4.70), Word accentuation OR: 2.99 (CI95% 1.25–7.53), and TMTA-1 timing 3.72 (CI95% 1.46–10.3) and the men with moderate versus low CVR. performed worse on MMSE-37 OR: 2.99 (CI95% 1.19–8.27). Conclusions: Higher CVR was associated with worse cognitive performance in the Spanish population 55–75 years old. The most affected cognitive domains were memory, attention and psychomotor speed.